ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a second round of radiation be safe for breast cancer patients?
Disease control Recruiting nowThis study is for women with ER+HER2- breast cancer who have already had radiation and now need a second lumpectomy. It tests whether giving another round of radiation to the same breast is safe and what side effects it may cause. The goal is to control the cancer and avoid a ful…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Youssef Zeidan • Aim: Disease control
Last updated May 16, 2026 23:42 UTC
-
New trial matches breast cancer patients to smarter treatments using tumor markers
Disease control Recruiting nowThis study is for people with metastatic breast cancer (cancer that has spread). It aims to see if choosing treatments based on specific tumor markers (biomarkers) can help control the disease longer. About 700 participants will receive standard therapies matched to their biomark…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 16, 2026 23:38 UTC
-
New combo aims to outsmart resistant breast cancer
Disease control Recruiting nowThis study compares two treatments for advanced estrogen receptor-positive (ER+) breast cancer that has stopped responding to standard therapies. About 297 participants will receive either a combination of elacestrant and capecitabine or capecitabine alone. The goal is to see if …
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New pill-and-shot combo aims to stop breast cancer growth before surgery
Disease control Recruiting nowThis study tests a daily pill called (Z)-endoxifen, sometimes combined with a monthly shot (goserelin) that temporarily stops the ovaries from making estrogen. The goal is to see if this treatment can slow or stop the growth of estrogen-receptor-positive, HER2-negative breast can…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Atossa Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo therapy aims to outsmart drug-resistant breast cancer
Disease control Recruiting nowThis study compares the hormone therapy elacestrant alone versus elacestrant combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) in 174 people with ER+/HER2- advanced or metastatic breast cancer who have already used a CDK4/6 inhibitor. The goal is to see i…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Smart dosing trial aims to tame metastatic breast cancer
Disease control Recruiting nowThis study tests a new way of giving the chemotherapy drug capecitabine to people with metastatic ER+ breast cancer. Instead of a fixed dose, the dose is adjusted based on how the tumor responds on scans and blood tests. The goal is to control the cancer for as long as possible w…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:40 UTC